PE20021092A1 - Antranilamidopiridinamidas selectivas como inhibidores de vegfr-2 y vegfr-3 - Google Patents
Antranilamidopiridinamidas selectivas como inhibidores de vegfr-2 y vegfr-3Info
- Publication number
- PE20021092A1 PE20021092A1 PE2002000384A PE2002000384A PE20021092A1 PE 20021092 A1 PE20021092 A1 PE 20021092A1 PE 2002000384 A PE2002000384 A PE 2002000384A PE 2002000384 A PE2002000384 A PE 2002000384A PE 20021092 A1 PE20021092 A1 PE 20021092A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- vegfr
- pyridin
- heteroaryl
- aryl
- Prior art date
Links
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 title abstract 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title abstract 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 title abstract 2
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 title 1
- 229940127432 VEGFR3 Inhibitors Drugs 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 abstract 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001123574 DE10123574A1 (de) | 2001-05-08 | 2001-05-08 | Selektive Anthranylamid-Derivate als VEGFR II Inhibitoren |
| DE2001125294 DE10125294A1 (de) | 2001-05-15 | 2001-05-15 | Selektive Anthranylamid-Derivate als VEGFR-2 und VEGFR-3 Inhibitoren |
| DE2001164590 DE10164590A1 (de) | 2001-12-21 | 2001-12-21 | Anthranylamidpyridinamide als VEGFR-2 und VEGFR-3 Inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021092A1 true PE20021092A1 (es) | 2003-01-11 |
Family
ID=27214428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000384A PE20021092A1 (es) | 2001-05-08 | 2002-05-08 | Antranilamidopiridinamidas selectivas como inhibidores de vegfr-2 y vegfr-3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040254185A1 (https=) |
| EP (1) | EP1392680B1 (https=) |
| JP (1) | JP2004528379A (https=) |
| KR (1) | KR20030094395A (https=) |
| CN (1) | CN1518546A (https=) |
| BR (1) | BR0209485A (https=) |
| CA (1) | CA2453223A1 (https=) |
| DE (1) | DE50213703D1 (https=) |
| IL (1) | IL158783A0 (https=) |
| MX (1) | MXPA03010099A (https=) |
| NO (1) | NO20034957D0 (https=) |
| PE (1) | PE20021092A1 (https=) |
| PL (1) | PL364478A1 (https=) |
| WO (1) | WO2002090352A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| CA2493026C (en) * | 2002-07-31 | 2011-05-24 | Bayer Schering Pharma Aktiengesellschaft | Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| JP2006526660A (ja) * | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｖｒ１レセプターのモジュレーター |
| DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
| US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
| CN1660811A (zh) * | 2004-02-27 | 2005-08-31 | 中国科学院上海药物研究所 | 1，4－二取代苯类化合物及其制备方法和用途 |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| KR20060071812A (ko) * | 2004-12-22 | 2006-06-27 | 주식회사 엘지생명과학 | 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 아민유도체 |
| WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
| EP1954696B1 (en) | 2005-01-19 | 2011-02-23 | Bristol-Myers Squibb Company | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
| JP4585978B2 (ja) * | 2005-03-03 | 2010-11-24 | 参天製薬株式会社 | キノリルアルキルチオ基を有する新規環式化合物 |
| WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| EP1899299B1 (en) | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| AR056867A1 (es) | 2005-06-27 | 2007-10-31 | Bristol Myers Squibb Co | Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas. |
| DE602006020871D1 (de) | 2005-06-27 | 2011-05-05 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden |
| US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| BRPI0619208A2 (pt) * | 2005-11-30 | 2011-09-20 | Astellas Pharma Inc | derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12 |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| AR065015A1 (es) * | 2007-01-26 | 2009-05-13 | Smithkline Beecham Corp | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer |
| FR2917413B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| EP2346827B1 (en) * | 2008-08-27 | 2013-11-13 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| IN2012DN02493A (https=) | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| KR101524923B1 (ko) * | 2013-08-02 | 2015-06-01 | 가톨릭대학교 산학협력단 | ＩＦＮ－γ의 발현을 증가시키는 ＶＥＧＦＲ－３ 억제제를 유효성분으로 포함하는 급성골수성백혈병 치료용 약학적 조성물 |
| CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
| CN106496107A (zh) * | 2016-08-31 | 2017-03-15 | 浙江永宁药业股份有限公司 | Vegfr‑2抑制剂及其制备方法 |
| CN108467360B (zh) * | 2018-06-22 | 2021-04-30 | 江苏美迪克化学品有限公司 | 一种阿帕替尼的制备方法及其中间体 |
| CN113228201B (zh) * | 2018-08-13 | 2023-03-07 | 健康科学西部大学 | 治疗青光眼的钙蛋白酶-2选择性抑制剂化合物 |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| CN117603175B (zh) * | 2023-11-27 | 2024-08-06 | 南开大学 | 一种苯并吡喃结构的查尔酮类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0686625B1 (en) * | 1993-12-27 | 1999-05-26 | Eisai Co., Ltd. | Anthranilic acid derivative |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| DE10023492A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| JP4343681B2 (ja) * | 2001-05-08 | 2009-10-14 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | シアノアントラニルアミド誘導体およびそれらの薬剤としての使用 |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2002
- 2002-05-03 MX MXPA03010099A patent/MXPA03010099A/es active IP Right Grant
- 2002-05-03 WO PCT/EP2002/004924 patent/WO2002090352A2/de not_active Ceased
- 2002-05-03 PL PL02364478A patent/PL364478A1/xx unknown
- 2002-05-03 KR KR10-2003-7014539A patent/KR20030094395A/ko not_active Ceased
- 2002-05-03 CN CNA028095804A patent/CN1518546A/zh active Pending
- 2002-05-03 IL IL15878302A patent/IL158783A0/xx unknown
- 2002-05-03 CA CA002453223A patent/CA2453223A1/en not_active Abandoned
- 2002-05-03 EP EP02735333A patent/EP1392680B1/de not_active Expired - Lifetime
- 2002-05-03 JP JP2002587431A patent/JP2004528379A/ja active Pending
- 2002-05-03 DE DE50213703T patent/DE50213703D1/de not_active Expired - Fee Related
- 2002-05-03 BR BR0209485-1A patent/BR0209485A/pt not_active IP Right Cessation
- 2002-05-03 US US10/477,119 patent/US20040254185A1/en not_active Abandoned
- 2002-05-08 PE PE2002000384A patent/PE20021092A1/es not_active Application Discontinuation
-
2003
- 2003-11-07 NO NO20034957A patent/NO20034957D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE50213703D1 (de) | 2009-09-03 |
| BR0209485A (pt) | 2004-07-06 |
| WO2002090352A2 (de) | 2002-11-14 |
| EP1392680B1 (de) | 2009-07-22 |
| KR20030094395A (ko) | 2003-12-11 |
| EP1392680A2 (de) | 2004-03-03 |
| PL364478A1 (en) | 2004-12-13 |
| MXPA03010099A (es) | 2004-03-10 |
| IL158783A0 (en) | 2004-05-12 |
| CA2453223A1 (en) | 2002-11-14 |
| NO20034957D0 (no) | 2003-11-07 |
| WO2002090352A3 (de) | 2003-05-01 |
| JP2004528379A (ja) | 2004-09-16 |
| CN1518546A (zh) | 2004-08-04 |
| US20040254185A1 (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021092A1 (es) | Antranilamidopiridinamidas selectivas como inhibidores de vegfr-2 y vegfr-3 | |
| PE20021002A1 (es) | Compuestos heterociclicos condensados | |
| PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
| CR7454A (es) | Compuestos quimicos | |
| EA200700545A1 (ru) | Производные изоксазолина и их применение в качестве гербицидов | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| EA200800873A1 (ru) | Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы | |
| PE20050747A1 (es) | Pirimidinas herbicidas | |
| PE20060316A1 (es) | Derivados de prolina como inhibidores de dipeptidil peptidasa-iv | |
| NZ589748A (en) | Sunfonyl-substituted bicyclic compounds as modulators of PPAR | |
| TW200736363A (en) | Material for organic electroluminescent device and organic electroluminescent device | |
| SE0300956L (sv) | Stabilisatorblandningar | |
| DE69405540D1 (de) | Substituierte kondensierte pyrazolverbindungen und ihre verwendung als herbizide | |
| AR061492A2 (es) | Procedimiento para la preparacion de compuestos intermediarios para la preparacion de 5-amino-1-aril-3-ciano pirazoles | |
| PE20030763A1 (es) | Inhibidores de la integrasa del vih | |
| PE20080427A1 (es) | Agentes antivirales | |
| SE0100903D0 (sv) | Compounds | |
| PE20030100A1 (es) | Compuestos de n-formil-hidroxilamina | |
| DE60100873D1 (de) | Eine kristallmodifikation von Celecoxib | |
| IL153016A0 (en) | Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines | |
| DK1447400T3 (da) | Bicyklisk forbindelse | |
| SE0103710D0 (sv) | Compounds | |
| AR067381A1 (es) | Derivados amido y/o amino tiofenos con actividad microbicida,composiciones que los contienen y usos de las mismas para prevenir y/o controlar la infeccion de plantas por microorganismos patogenos,preferentemente hongos. | |
| ES8800166A1 (es) | Procedimiento para la obtencion de imidazoles sustituidos | |
| PE20020905A1 (es) | Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |